Recently published data reinforce the vaccine researchers to reconsider two main facts in Leishmania vaccine: the chronic parasitic infection after successful healing of primary infection (which has recently highlighted novel aspects of immunity to reinfection mediated by CD4+ T cells) and sandfly challenge infection instead of needle challenge. The gene discussed is CD4; the disease is infection.